SCHEMBL24423596

SCHEMBL24423596

COc1cc(-c2cc(C(=O)N3CCC(C(=O)NCc4ccc(C(F)(F)F)nc4)CC3)n[nH]2)c(Cl)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 1/20 0.43
▸ PRKAA2 P54646 3/20 0.42
▸ PRKAB2 O43741 1/20 0.42
▸ PRKAG1 P54619 1/20 0.42
▸ PRKAA1 Q13131 1/20 0.42
▸ PRKAG3 Q9UGI9 1/20 0.42
▸ PRKAG2 Q9UGJ0 1/20 0.42
▸ PRKAB1 Q9Y478 1/20 0.42
▸ POLB P06746 1/20 0.40
▸ CA12 O43570 3/20 0.40
▸ CA1 P00915 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA9 Q16790 3/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ ACHE P22303 1/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KDM5A P29375 1/20 0.39
▸ PIK3CA P42336 2/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29243527 0.92 KMT2A (0.43) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL30630497 0.92 KMT2A (0.43) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL29585763 0.90 MEN1 (0.44) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL29243378 0.90 MEN1 (0.44) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL24423844 0.89 EPHX2 (0.44) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL24424319 0.88 CDK9 (0.39) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL24424388 0.87 PRKAB2 (0.37) PTGESPRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL29243543 0.87 CHEK1 (0.48) POLBCA12CA1CA2CA9
SCHEMBL29585273 0.87 CHEK1 (0.48) POLBCA12CA1CA2CA9
SCHEMBL24423868 0.87 ACHE (0.43) POLBCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN claimed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD PTGES 253/4885PRKAA2 126/4885PRKAB2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback